Cathie Wood's ARK Invest purchased additional CoreWeave shares on Wednesday, October 14, 2026, adding to its position in the AI cloud infrastructure provider following a steep single-day decline, while also selling stakes in Palantir Technologies, Personal Genome Diagnostics, and several other companies, according to the firm's daily trade disclosures. The firm's U.S. actively managed ETFs publish their trades each trading day, giving the public a same-day view into portfolio shifts that most funds disclose only quarterly.

ARK's CoreWeave Purchase

ARK bought 188,665 shares of CoreWeave, Inc. Class A common stock (CRWV), valued at $14,680,023 in the daily trade report. Another report placed the value of the purchase at about $12.4 million.

CoreWeave stock fell 15.5% in regular trading on Wednesday and is down 53% over the past 12 months, as concerns about the company's financial obligations weigh on investors. Shares slipped another 3.5% in after-hours trading. The purchase increases ARK's exposure to a stock trading at less than half its level of a year ago.

CoreWeave's Debt Concerns

The yield on CoreWeave's $1.25 billion in unsecured bonds due in 2032 recently touched 15%, a level at which credit investors demand a substantial premium over safer corporate borrowings, lifting the cost of new debt for the company as it explores fresh financing options. Venture capitalist Chamath Palihapitiya warned about possible trouble in AI infrastructure financing, drawing a one-word reply from Elon Musk: “Yikes.”

The Financial Times reported that CoreWeave is exploring financing from life insurance companies. The company hopes to secure investment-grade financing backed by its computing infrastructure. CoreWeave carried debt and lease obligations of about $52 billion as of June, a scale that reflects the capital-intensive nature of AI infrastructure, where providers fund data centers and GPU capacity through heavy borrowing and leasing.

Sentiment was further pressured on Wednesday by hotter-than-expected September inflation data, which raised concerns about additional Federal Reserve interest rate hikes. Companies carrying large debt loads are typically more sensitive to shifts in rate expectations.

Despite the turbulence, Wall Street rates CoreWeave a Moderate Buy, with 20 Buy ratings, 5 Holds, and 2 Sells over the past three months. The average price target of $143.96 is about 119% above Wednesday's close. Follow-through to watch includes ARK's next daily trade disclosures, trading in the 2032 bonds as a gauge of credit-market sentiment, and any update from CoreWeave on the life-insurer financing discussions reported by the Financial Times.

Palantir and Other ARK Trades

ARK sold 31,432 Palantir shares, valued at $6,558,915 in the trade report, though another report put the figure near $6.3 million. The sale followed a strong run for the data analytics software maker, whose stock has risen more than 60% since early-August earnings, when second-quarter revenue climbed 93% from a year earlier to $1.94 billion. Palantir shares fell 3.7% on Wednesday.

Barclays recently initiated coverage of Palantir at Overweight with a $265 price target, while Goldman Sachs upgraded the stock to Buy with a $230 target. Palantir, which joined the S&P 500 in September 2024, trades at 163.9 times trailing earnings and 85.5 times expected profits. Its average price target of $210.67 points to a 5% gain.

In other portfolio moves, ARK sold 693,049 shares of Personal Genome Diagnostics for $10,984,826 and 113,555 shares of 10X Genomics for $8,152,113. The firm also sold 337,473 shares of Toast for $10,424,540 and 25,605 shares of Shopify for $4,519,794.

On the buying side, ARK purchased 9,577 shares of Meta Platforms for $7,302,462, 44,689 shares of Cerebras Systems for $6,662,683, and 110,037 shares of Freenome for $1,390,867. The firm also added 500,457 shares of Kodiak and bought 459 shares of Scribe Therapeutics for $8,776.